Johnson & Johnson (JNJ) Stock Grade

About Johnson & Johnson's fundamentals

Johnson & Johnson is a major pharmaceutical company with a $504.1 billion market valuation that generated 6.1% year-over-year revenue growth and maintains an impressive 28.5% net profit margin, indicating strong pricing power and operational efficiency in its drug manufacturing business. The company delivers a 32.9% return on equity, demonstrating effective capital deployment, while trading at a P/E ratio of 18.8 and offering a 2.5% dividend yield. These metrics suggest a mature, profitable business with substantial cash generation capabilities relative to its earnings and market value.